Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Apr;37(2):269-271.
doi: 10.1097/JCP.0000000000000659.

Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder

Thomas G Adams  1 , Michael H Bloch, Christopher Pittenger
Affiliations
Case Reports

Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder

Thomas G Adams et al. J Clin Psychopharmacol. 2017 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Change in OCD [Yale-Brown Obsessive-Compulsive Scale (YBOCS)] and MDD [Montgomery-Asberg Depression Rating Scale (MADRS)] severity (right axis) were modest following ketamine and CBT (shaded area) but suicidality (MADRS item 10, left axis) drastically reduced following the first week of ketamine treatment.
See this image and copyright information in PMC

References

    1. Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther. 2011;132:314–332. - PMC - PubMed
    1. Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38:2475–2483. - PMC - PubMed
    1. Bloch MH, Wasylink S, Landeros-Weisenberger A, et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012;72:964–970. - PMC - PubMed
    1. Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med. 2015;66:509–523. - PMC - PubMed
    1. Rodriguez Cl, Wheaton M, Zwerling J, et al. Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial. J Clin Psychiatry. 2016;77:408–409. - PMC - PubMed

MeSH terms